

Metastatic hormone-sensitive prostate cancer. How should it be tre: X

ALL

IMAGES

VIDEOS

8,740,000 Results

Any time ▾

Combination systemic therapy is now standard of care for all men with metastatic, hormone-sensitive prostate cancer (mHSPC). Patients with mHSPC should be treated with standard androgen deprivation therapy (ADT) and abiraterone acetate with prednisone or docetaxel (chemohormoanl therapy) unless there are contraindications to combination therapy.

Author: Adam B Weiner, Oluwarotimi S Netey, Alicia K Morgans

Cited by: 3

Publish Year: 2019

[Management of Metastatic Hormone-Sensitive Prostate Cancer ...](#)

pubmed.ncbi.nlm.nih.gov/31286275/

Was this helpful?  

PEOPLE ALSO ASK

What is the treatment for metastatic prostate cancer? ▾

How does prostate cancer spread? ▾

What is the surgical treatment for prostate cancer? ▾

Is Erleada approved for prostate cancer? ▾

Feedback

[Metastatic Prostate Cancer Treatment Options: An Expert ...](#)

<https://www.healthline.com/health/prostate-cancer/...> ▾

Apr 28, 2020 · The main pathway for treating metastatic prostate cancer (mCaP) focuses on starving the disease of testosterone (androgen). In 1941, medical researchers Huggins and Hodges first ...

[Management of Metastatic Hormone-Sensitive Prostate ...](#)

<https://pubmed.ncbi.nlm.nih.gov/31286275>

Combination systemic therapy is now standard of care for all men with metastatic hormone-sensitive

<https://cn.bing.com/images/search?q=Metastatic+hormone-sensitive+prostate+cancer.+How+should+it+be+treated?&FORM=HDRSC2>

国内版 国际版

Metastatic hormone-sensitive prostate cancer. How should it be tre



ALL

IMAGES

VIDEOS

8,430,000 Results

Any time ▾

Combination systemic therapy is now standard of care for all men with metastatic, hormone-sensitive prostate cancer (mHSPC). Patients with mHSPC should be treated with standard androgen deprivation therapy (ADT) and abiraterone acetate with prednisone or docetaxel (chemohormoanl therapy) unless there are contraindications to combination therapy.

Author: Adam B Weiner, Oluwarotimi S Nettey, Alicia K Morgans

Cited by: 3

Publish Year: 2019

[Management of Metastatic Hormone-Sensitive Prostate Cancer ...](#)

pubmed.ncbi.nlm.nih.gov/31286275/

Was this helpful?

PEOPLE ALSO ASK

What is the treatment for metastatic prostate cancer? ▾

How does prostate cancer spread? ▾

What is the surgical treatment for prostate cancer? ▾

Can hormone drug treatment cure prostate cancer? ▾

Feedback

Name of Journal: *World Journal of Clinical Oncology*

Manuscript NO: 59742

Manuscript Type: EDITORIAL

Metastatic hormone-sensitive prostate cancer: How should it be treated?

Metastatic hormone-sensitive prostate cancer

Abstract

The number of treatment options for metastatic hormone-sensitive prostate cancer (mHSPC) has increased substantially in recent years. The classic treatment approach for these patients— androgen deprivation therapy (ADT) alone—is now considered suboptimal. Several randomized phase III clinical trials have demonstrated significant clinical benefits—including significantly better overall survival (OS) and quality of life (QoL)—for treatments that combine ADT with docetaxel, abiraterone acetate, enzalutamide, apalutamide, and/or radiotherapy to the primary tumour. As a result,

Match Overview

1	Crossref 25 words Yu Wei, Junlong Wu, Weijie Gu, Jun Wang, Guowen Lin, Xiaojian Qin, Bo Dai, Huafei Gan, Dingwei Ye, Yao Zhu. "Prognosti	1%
2	Crossref 16 words "Principles and Practice of Urooncology", Springer Science and Business Media LLC, 2017	1%
3	Crossref 12 words Cattini, Castro, Lozano, Zanardi, Rubagotti, Boccardo, Olmi... s. "Current Treatment Options for Metastatic Hormone-Sensi	1%
4	Internet 12 words crawled on 09-Sep-2020 journals.sagepub.com	1%

国内版 国际版

Metastatic hormone-sensitive prostate cancer: How should it be tre:



ALL

IMAGES

VIDEOS

7,600,000 Results

Any time ▾

Combination systemic therapy is now standard of care for all men with metastatic, hormone-sensitive prostate cancer (mHSPC). Patients with mHSPC should be treated with standard androgen deprivation therapy (ADT) and abiraterone acetate with prednisone or docetaxel (chemohormoanl therapy) unless there are contraindications to combination therapy.

Author: Adam B Weiner, Oluwarotimi S Nette, Alicia K Morgans

Cited by: 4

Publish Year: 2019

[Management of Metastatic Hormone-Sensitive Prostate Cancer ...](#)

► pubmed.ncbi.nlm.nih.gov/31286275/

Was this helpful?

PEOPLE ALSO ASK

What is the treatment for metastatic prostate cancer? ▾

How does prostate cancer spread? ▾

What is the surgical treatment for prostate cancer? ▾

Can hormone drug treatment cure prostate cancer? ▾

Feedback

[Management of Metastatic Hormone-Sensitive Prostate ...](#)

<https://pubmed.ncbi.nlm.nih.gov/31286275/>

Combination systemic therapy is now standard of care for all men with metastatic, hormone-sensitive prostate cancer (mHSPC). Patients with mHSPC should be treated with standard **androgen deprivation therapy (ADT)** and abiraterone acetate with prednisone or docetaxel (chemohormoanl therapy) unless there are contraindications to combination therapy. Based on the Chemohormonal Therapy Versus ...

Cited by: 4

Author: Adam B Weiner, Oluwarotimi S Nette, Al...